Correction: Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA.

Bibliographic Details
Main Author:	PLOS ONE Staff
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2015-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC4546425?pdf=render

id	doaj-728338d8b7c24a8fab3984d50a9e0d88
record_format	Article
spelling	doaj-728338d8b7c24a8fab3984d50a9e0d882020-11-25T01:26:22ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01108e013651510.1371/journal.pone.0136515Correction: Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA.PLOS ONE Staffhttp://europepmc.org/articles/PMC4546425?pdf=render
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	PLOS ONE Staff
spellingShingle	PLOS ONE Staff Correction: Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA. PLoS ONE
author_facet	PLOS ONE Staff
author_sort	PLOS ONE Staff
title	Correction: Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA.
title_short	Correction: Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA.
title_full	Correction: Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA.
title_fullStr	Correction: Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA.
title_full_unstemmed	Correction: Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA.
title_sort	correction: treatment frequency and dosing interval of ranibizumab and aflibercept for neovascular age-related macular degeneration in routine clinical practice in the usa.
publisher	Public Library of Science (PLoS)
series	PLoS ONE
issn	1932-6203
publishDate	2015-01-01
url	http://europepmc.org/articles/PMC4546425?pdf=render
work_keys_str_mv	AT plosonestaff correctiontreatmentfrequencyanddosingintervalofranibizumabandafliberceptforneovascularagerelatedmaculardegenerationinroutineclinicalpracticeintheusa
_version_	1725109406532632576

Correction: Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA.

Similar Items